Press Releases

Date Title and Summary View
Toggle Summary Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today
Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis NORCROSS, Ga., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins,
View HTML
Toggle Summary Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020
Presentation to discuss the details of the newly launched Phase 2b/3 NASH-RX clinical trial; Introduce new CEO and President Joel Lewis NORCROSS, Ga., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins,
View HTML
Toggle Summary Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
NORCROSS, Ga., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the H.C. Wainwright 22 nd Annual Virtual Global Investment Conference, on Monday,
View HTML
Toggle Summary Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer
Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board Board strengthened in scientific expertise with addition of Dr. Elissa Schwartz and in business expertise with Mr. Richard Zordani NORCROSS, Ga. , Sept.
View HTML
Toggle Summary Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update
NASH-RX Trial Continues to Enroll New Patients NORCROSS, Ga. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June
View HTML
Toggle Summary Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this patient population Compelling NASH-RX trial result could potentially lead to accelerated FDA approval
View HTML
Toggle Summary Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update
NASH-RX Clinical Trial Protocol Filed with FDA; First Patient Currently Expected to be Enrolled in Second Quarter 2020 Filed a New Form S-3 Shelf Registration Statement Which Replaces the Company’s Existing Shelf Registration Statement, which Expires on June 1, 2020 NORCROSS, Ga.
View HTML
Toggle Summary Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis
The first patient currently expected to be enrolled in the second quarter of 2020 NORCROSS, Ga. , April 30, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has submitted to the U.S.
View HTML
Toggle Summary Galectin Therapeutics Update on the Impact of COVID-19
NORCROSS, Ga. , April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities.
View HTML
Toggle Summary Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update
Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of esophageal varices in patients with NASH cirrhosis NORCROSS, Ga. , March 16, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
View HTML